【摘要】 近年来全国耐碳青霉烯类肺炎克雷伯菌(CRKP)分离率逐年上升，且由于其多重耐药、病死率高的特点，给临床治疗带来了严峻挑战。CRKP耐药最主要机制为产碳青霉烯酶，在CRKP中常见的碳青霉烯酶类型为Ambler A、B、D类，C类少见。碳青霉烯酶中最常见的是肺炎克雷伯菌碳青霉烯酶(KPC),属于A类。产KPC肺炎克雷伯菌(KPC-KP)在全球范围内广泛扩散，临床有效治疗药物非常有限。本文就KPC-KP感染治疗的研究进展进行总结，以期为临床治疗提供借鉴意义。更多还原

【Abstract】 In recent years, the isolation rate of carbapenem-resistant Klebsiella pneumoniae(CRKP) in China has increased year by year. Due to its multidrug resistance and high mortality in patients, CRKP brings severe challenges to the clinical treatment. The major mechanism of drug resistance in CRKP is the production of carbapenemases, with Ambler A, B, and D being the common types while Ambler type C comparativly rare. Klebsiella pneumoniae carbapenemase(KPC) is the most common carbapenemase, which belongs to type A. KPC-producing Klebsiella pneumoniae(KPC-KP) widely spreads in the world, with very limited number of effective clinical drugs. In this review, advances in the treatment KPC-KP were summarized to provide reference for clinical treatment.更多还原